10/16/2013 6:46:41 AM
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals business, today announced financial guidance for its fiscal year ending September 26, 2014.
For fiscal 2014, the company’s annual net sales are expected to be in the range of $2.15 billion to $2.25 billion on an operational basis, which excludes the impact of fluctuations in foreign currency exchange rates1.
Help employers find you! Check out all the jobs and post your resume.
comments powered by